<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34955">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660620</url>
  </required_header>
  <id_info>
    <org_study_id>108298</org_study_id>
    <nct_id>NCT01660620</nct_id>
  </id_info>
  <brief_title>Topical Betaxolol for the Prevention of Retinopathy of Prematurity</brief_title>
  <official_title>Topical Betaxolol for the Prevention of Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith-Kettlewell Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Smith-Kettlewell Eye Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that topical betaxolol will reduce the development of severe retinopathy of
      prematurity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime
      when ROP is most likely to arise.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>development of apnea and or bradycardia</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>babies were monitored and HR/RR monitored and recorded by masked observers, periodically</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>development of ROP requiring treatment</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Type I ROP was used as a secondary outcome measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Development of Side Effects From Betaxolol</condition>
  <arm_group>
    <arm_group_label>betaxolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>betaxolol 0.25% 2 per day for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>masked labeling also 2 per day administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaxolol</intervention_name>
    <arm_group_label>betaxolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical betaxolol</intervention_name>
    <description>given topically</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;1251 grms birth weight

        Exclusion Criteria:

          -  ocular defect
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>32 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>January 2, 2013</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Smith-Kettlewell Eye Research Institute</investigator_affiliation>
    <investigator_full_name>William V Good, MD</investigator_full_name>
    <investigator_title>Administrator</investigator_title>
  </responsible_party>
  <keyword>betaxolol/ retinopathy of prematurity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betaxolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
